medigraphic.com
ISSN 0188-2198 (Print)

2003, Number 4

Next >>

Rev Mex Cardiol 2003; 14 (4)

Nadroparina cálcica y clopidogrel en pacientes sometidos a intervención coronaria percutánea con colocación de stents

Padilla-Padilla F, Reyes F, Ariza H, Montoya A, Ledesma M, Escudero X, Palomo A, Astudillo R, Abundes A, Flores J, Estrada J, Farell-Campa J

Language: Spanish
References: 42
Page: 111 - 117
PDF size: 86.09 Kb.


ABSTRACT

Introduction: Thrombosis has a relevant role in interventional complications like acute vessel closure after stenting. Low molecular weight heparin such as nadroparin calcium, has certain advantages over unfractionated heparin (UFH), specially in prevention of thrombosis. The main objective of this study, it’s compare efficacy between nadroparin calcium and UFH in prevention for acute closure or acute stent thrombosis after percutaneous coronary intervention (PCI). Methods: The trial was a randomized, simple blind, prospective and comparative study. A number of 38 eligible patients were randomized to be treated with 86 UI AXa/ kg of nadroparin or 70 UI/kg of UFH during ICP and stenting. Statistical analysis was performed with mean, standard deviation, Chi-square, Fisher’s test and t Student. Results: A total of 38 patients were treated, we assigned 18 patients to receive nadroparin and 20 patients with UFH. The incidence of myocardial infarction was 0% nadroparin vs 10% to UFH (p = 0.270), acute closure 5.6% vs 10% (p = 0.541), hemorrhagic complications 0 vs 10% (p = 0.270) and mortality 5.6 vs 0% (p = 0.474) respectively. Conclusions: The use of nadroparin showed similar efficacy and safety as UFH in the treatment of patients with PCI and Stenting.


REFERENCES

  1. Noble S, Spencer C. Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56(2): 259-272.

  2. Fox K. Low molecular weight heparins in acute coronary syndromes. Eur Heart J 1998; 19: 817-819.

  3. Preisack M, Bonan R, Meisner C. Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. Eur Heart J 1998; 19: 1232-1238.

  4. Rutsch W, Baumann G. Anticoagulation in interventional cardiology optimizing patient outcome. Eur Heart J 1998; 19(Suppl. K): K11-K17.

  5. Garachemani A, Meier B. Heparin for coronary angioplasty: high dose, low dose, or no dose? Heart 1998; 80: 3-4.

  6. Ragosta M, Karve M, Brezynski D. Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention. Am Heart J 1999; 137: 250-257.

  7. Matthai W, Kurnik P, Groh W. Antithrombin activity during the period of percutaneous coronary revascularization. JACC 1999; 33: 1248-56.

  8. Bertrand M, Rupprecht H, Urban P. Double-blind study of the safety of clopidogrel with and without loading dose in combination with aspirin after coronary stenting. CLASSICS. Circulation 2000; 102: 624-629.

  9. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? JACC 2000; 35(7): 1699-712.

  10. Shaknovich A. Complications of coronary stenting. Coronary Artery Dis 1994; 5: 583-589.

  11. Roubin G, Cannon A, Agrawal S. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992; 85: 916-927.

  12. George B, Voorhees W, Roubin G. Multicenter investigation of coronary stenting to treat acute or threatened closure complicating percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. JACC 1993; 22: 135-143.

  13. Topol E. Caveats about elective coronary stenting. N Engl J Med 1994; 331: 539-541.

  14. Schömig A, Neummann F, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary Stents. N Engl J Med 1996; 334: 1084-1089.

  15. Bertrand M, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597-1603.

  16. Leon M, Baim D, Popma J. A clinical trial comparing 3 antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998; 339: 1665-1671.

  17. Urban P, Macaya C, Rupprecht H. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk patients. Circulation 1998; 98: 2126-2132.

  18. Herbert J, Frehel D, Valle E. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.

  19. CAPRIE Steering committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

  20. Harker L, Marzec U, Kelly A. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998; 22: 2461-2469.

  21. Makkar R, Eigler S, Kaul S. Effects of clopidogrel, aspirin, and combined therapy in a porcine exvivo model of high shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.

  22. Turpie A. Can we differentiate the low molecular weight heparins? Clin Cardiol 2000; 23(Suppl. 1): 14-17.

  23. The Frax I.S. group study. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 days treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. Eur Heart J 1999; 20(21): 1553-1562.

  24. Antman E, Radley D, Cohen M. Assessment of the treatment effect of enoxaparin for unstable angina/ non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100(15): 1602-8.

  25. Zed P, Tisdale J, Borzak, E. Low molecular weight heparins in the management of acute coronary syndromes. Arch Intern Med 1999; 159(16): 1849-57.

  26. Winter R, Levi M, Adams R. Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Fraxiparin Anticoagulant Therapy in Myocardial Infarction Study Amsterdam. Heart 1998; 80(1): 35-9.

  27. Mark D, Cowper P, Berkowitz S. Economic analysis of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702-7.

  28. Cohen M, Demers C, Gurfinkel E. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease (ESSENCE trial). N Engl J Med 1997; 337: 447-52.

  29. Serruys P, Herrman J, Simon R. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. HELVETICA Investigators. N Engl J Med 1995; 333: 757-63.

  30. The EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.

  31. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.

  32. The EPILOG investigators. Platelet Glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.

  33. Karsch K. Low molecular weight heparin in prevention of restenosis after PTCA, the REDUCE trial. JACC 1996; 28: 1437-43.

  34. Cairns J, Gill J, Morton B. EMPAR collaborators. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR study. Circulation 1996; 94: 1553-60.

  35. Faxon D, Spiro T, Minor S. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994; 90: 908-14. 36.Lablanche J, McFadden E, Meneveau N. Effect of nadroparin, a low molecular weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty. The FACT study. Circulation 1997; 96: 3396-402.

  36. Kruse K. Enoxaparin and Ticlopidine After Elective Stenting, the ENTICES trial. JACC 1997; 27: 34A.

  37. Gasperetti C, Gonias S, Gimple L. Platelet activation During coronary angioplasty in humans. Circulation 1993; 88: 2728-34.

  38. Lincoff A, Popma J, Ellis S. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic, and therapeutic profile. JACC 1992; 19: 926-35.

  39. Wilcox J. Thrombin and other potential mechanisms underlying restenosis. Circulation 1991; 84: 432-5.

  40. Bittl J, Strony J, Brionker J. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.

  41. Antman E, McCabe C, Gurfinkel E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Qwave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI ) 11B trial. Circulation 1999; 100: 1593-1601.

  42. Hanke H, Oberhoff M, Hanke S. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular weight heparin. Circulation 1992; 85: 1548-1556.




2020     |     www.medigraphic.com